Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products
MWN-AI** Summary
Ginkgo Bioworks (NYSE: DNA) has partnered with Invaio Sciences to advance the manufacturing of peptide-based agricultural products aimed at enhancing crop protection. This collaboration comes in light of the growing challenges faced by farmers due to pests that are increasingly resistant to traditional pest control methods. Invaio Sciences is recognized for its nature-positive crop protection solutions, focusing on effective peptide-based alternatives to conventional agricultural chemicals.
Under this partnership, Ginkgo will utilize its innovative platform, which includes high-efficiency microbial strains and advanced fermentation processes, to enable Invaio to scale up the production of its peptide-based solutions. By optimizing these microbial strains, Ginkgo aims to foster a cost-effective and scalable method for agricultural product development, thereby allowing Invaio to continue its focus on discovering next-generation biological solutions for crop protection.
Invaio's CEO, Amy O'Shea, expressed confidence in this collaboration, stating that Ginkgo's technology provides a clear strategy for producing peptides at an industrial scale. Jill Bradshaw, General Manager of Ginkgo’s Microbial Solutions unit, emphasized the urgent need for sustainable agricultural solutions that meet the demands of growers and benefit the environment.
Through this collaboration, both companies aim to develop manufacturing capabilities that will support growers in addressing pest challenges while adhering to eco-friendly practices. The partnership reflects a commitment to harnessing biotechnology for the continued advancement of agricultural methods that align with modern sustainability principles. This initiative reinforces Ginkgo's position in the biomanufacturing landscape, as it gears up to support diverse agricultural innovations in the market.
MWN-AI** Analysis
The recent collaboration between Ginkgo Bioworks (NYSE: DNA) and Invaio Sciences marks a significant development in the agricultural biotechnology sector, emphasizing the need for innovative pest management solutions as traditional methods face mounting resistance issues. This partnership aims to harness Ginkgo's advanced microbial platforms to optimize the manufacturing process of peptide-based crop protection inputs, promising a shift toward more sustainable farming practices.
From a market perspective, this collaboration represents a bullish opportunity for Ginkgo Bioworks. With increasing global demand for sustainable agricultural practices, Ginkgo's expertise in gene editing and fermentation technology positions it favorably to capture a growing share of the biopesticide market. Investors should note that Ginkgo's focus on scalability via its autonomous labs provides it with a competitive advantage, potentially allowing for rapid commercial deployment of effective solutions.
Invaio’s nature-positive approach resonates with shifting consumer preferences towards sustainable products, further enhancing its market appeal. The partnership not only plays into current agricultural needs but also addresses future demands for environmentally friendly farming solutions as regulatory pressures increase on chemical pest controls.
For investors, this collaboration could mean significant growth potential for both companies. Ginkgo's innovative solutions may foster advancements in bioproducts, enhancing revenue streams and driving stock performance. However, potential investors should remain aware of inherent risks attached to biotechnology ventures, including regulatory hurdles, market acceptance, and technological feasibility.
In summary, the partnership between Ginkgo Bioworks and Invaio Sciences showcases a strategic move in developing sustainable agricultural technologies. For those looking to invest, Ginkgo presents an interesting, albeit risky, opportunity in a burgeoning sector that aligns with broader environmental goals. Careful evaluation of market trends and ongoing developments in biopesticides will be crucial for investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costs
BOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo") and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs.
Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chemistry. In response, Invaio's platform discovers and develops peptide-based crop protection solutions that complement or offer potent alternatives to conventional chemistry while meeting growers' standards for efficacy, affordability, and ease of use.
As a part of the commercialization of its peptide-based products, Invaio will leverage Ginkgo's platform and best-in-class microbial strains for protein production. Ginkgo's strains have been engineered to provide advanced starting points for protein and peptide-based products through industrial-scale fermentation. In this collaboration, Ginkgo will further optimize its strains and fermentation processes to deliver on Invaio's production goals.
"Ginkgo's technology offers us a clear path to manufacturing our peptides at scale," said Amy O'Shea, CEO of Invaio Sciences. "We are excited to partner with Ginkgo to develop much-needed next generation crop protection solutions for persistent pests and diseases."
This collaboration demonstrates Invaio's commitment to developing scalable and cost effective peptide-based crop protection solutions that fits into and complements growers' existing practices. It highlights the value of Ginkgo's technologies in helping biotechnology companies efficiently optimize different stages of product development, including scale-up and manufacturing. As part of this program, Ginkgo will perform key protocols using its autonomous lab infrastructure, including Reconfigurable Automation Carts (RACs) and Catalyst automation software.
"At Ginkgo, we understand the urgency for next-generation agricultural solutions that can support growers, consumers and the planet," Jill Bradshaw, General Manager of Ginkgo's Microbial Solutions business unit says. "We are excited to work alongside our partners at Invaio to deliver a manufacturing strain and process that allows them to continue to focus on the discovery of next-generation biological solutions important to crop protection."
Ginkgo's platform supports partners at various stages of scale-up and manufacturing: from production strain licensing and engineering to bioprocess development and scale-up.
To learn more, visit Invaio.com or www.ginkgo.bio/
About Ginkgo Bioworks:
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
About Invaio Sciences:
Invaio Sciences, a Flagship Pioneering company, is a bioplatform company accelerating the leap to nature-positive agriculture. Building on advances in human health and leveraging proprietary GenAI tools, Invaio is uniquely positioned to design and develop peptide solutions for crop health with performance on par to conventional crop protection chemistries, enabling farmers to both improve yields and use more natural solutions. By leading in nature-positive technologies, Invaio is addressing consumer demands and unlocking radical benefits for farmers and the environment, leaving every acre better today and for generations to come. For more information, please visit www.invaio.com or follow Invaio on LinkedIn.
INVAIO SCIENCES CONTACT:
media@invaio.com
GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
SOURCE Ginkgo Bioworks
FAQ**
How is Ginkgo Bioworks Holdings Inc. Class A DNA leveraging its autonomous lab infrastructure to optimize the manufacturing processes for the peptide-based crop protection solutions developed in collaboration with Invaio Sciences?
What specific advantages does the partnership between Ginkgo Bioworks Holdings Inc. Class A DNA and Invaio Sciences offer in addressing the rising resistance of pests to conventional crop protection methods?
In what ways does Ginkgo Bioworks Holdings Inc. Class A DNA plan to ensure the scalability and cost-effectiveness of the peptide-based agricultural products developed through this collaboration with Invaio Sciences?
How will the collaboration between Ginkgo Bioworks Holdings Inc. Class A DNA and Invaio Sciences contribute to the overall goal of nature-positive agriculture and meet consumer demands for sustainable crop protection solutions?
**MWN-AI FAQ is based on asking OpenAI questions about Ginkgo Bioworks Holdings Inc. Class A (NYSE: DNA).
NASDAQ: DNA
DNA Trading
-4.32% G/L:
$6.54 Last:
512,033 Volume:
$6.60 Open:
